27.70
-1.07%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fluicell
Its shares trade on Nasdaq Stockholm under the ticker FLUI.ST. It has been listed since 18 April 2018. In the fiscal year to 31 December 2025, it reported revenue of SEK 6.0m and a net loss of SEK 8.3m. At that date it held total assets of SEK 18.5m and shareholders' equity of SEK 10.9m.
Fluicell AB engages in the provision of fluid platforms for multi-functional pipettes for cell-based pharmacology research. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2018-04-18. The company commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Apr 2018
- Website
- fluicell.com ↗
Leadership
Pay as last reported
- Mr. Stefan TilkIndependent Chairman of the Board
- Dr. Victoire ViannayChief Executive Officer, since 2017SEK 768,220
- Mr. Mats JonassonChief Financial OfficerSEK 336,000
- Mr. Joakim WahlbergChief Financial Officer
- Dr. Gavin JeffriesChief Technology Officer, DirectorSEK 636,615
- Ms. Tatsiana LobovkinaChief Scientific Officer
- Ms. Carolina TrkuljaChief Innovation Officer
- Prof. Owe OrwarDirector
- Prof. Daniel ChiuIndependent Director
- Mr. Carl FhagerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fluicell AB's BioPen enables precise cell manipulation for drug development research.
- Dynaflow Resolve processes and measures drug impact on individual cells effectively.
- Biopixlar Retina creates complex tissue-like structures in 2D and 3D formats.
Weaknesses
- Fluicell AB's commercialization is limited to cell-based pharmacology research applications.
- The company's product portfolio focuses on niche research tools without broader market expansion.
- Fluicell AB's operations are based in Moelndal, Sweden, restricting global reach.
Opportunities
- Expanding Biopixlar Retina's use in 3D bioprinting for advanced tissue engineering.
- Increasing demand for cell-based research tools in drug development sectors.
- Collaborating with pharmaceutical companies in Sweden and Europe for market growth.
Threats
- Competition from established biotechnology firms in the Health Care sector.
- Regulatory changes affecting cell-based research and drug development processes.
- Economic downturns impacting funding for pharmaceutical research initiatives.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.